Current Report Filing (8-k)
16 Juin 2023 - 10:02PM
Edgar (US Regulatory)
0001213660
false
0001213660
2023-06-16
2023-06-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): June
16, 2023
BIMI International Medical Inc. |
(Exact name of registrant as specified in its charter) |
Delaware |
|
001-34890 |
|
02-0563302 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
725 5th Avenue, 15th Floor, 15-01
New York NY |
|
10022 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code: 212 542 0028
|
(Former name or former address, if changed since last report) |
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common stock, $0.001 par value |
|
BIMI |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On June
15, 2023, BIMI International Medical Inc. (the “Company”) received formal notification from The Nasdaq Stock Market LLC confirming
that the Company had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), which requires that
the Company’s common stock maintain a minimum bid price of at least $1.00 per share.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: June 16, 2023 |
BIMI International Medical Inc. |
|
|
|
By: |
/s/ Tiewei Song |
|
Name: |
Tiewei Song |
|
Title: |
Chief Executive Officer |
BIMI International Medical (NASDAQ:BIMI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
BIMI International Medical (NASDAQ:BIMI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024